NCT07137390 2026-03-11
A Trial of Regorafenib Plus Lorigerlimab as Neoadjuvant Therapy for Patients With pMMR/MSS, Resectable, Lung-limited Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
Clinical Trials
191 trialsNCT06608940 2026-02-19
BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma
Case Comprehensive Cancer Center
Phase 1/2 Withdrawn
NCT06284460 2026-02-13
Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT04273555 2026-02-06
Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients With Advanced PET/MR Imaging
University of Alabama at Birmingham
Phase 1/2 Withdrawn
NCT04129515 2026-01-02
NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis
Brown University
Phase 1/2 Withdrawn
NCT04031872 2025-09-05
LY3200882 and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer (EORTC1615)
The Netherlands Cancer Institute
Phase 1/2 Withdrawn
NCT06361810 2025-08-19
PSMA Therapy and Immunotherapy in Kidney Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Withdrawn
NCT05538988 2025-06-27
BIOSELECT
AHS Cancer Control Alberta
Phase 1/2 Withdrawn
NCT05672095 2025-05-23
Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer
City of Hope Medical Center
Phase 1/2 Withdrawn
NCT02756130 2025-05-13
Birinapant and Carboplatin in Treating Patients and Targeting Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (HGSOC)
Jonsson Comprehensive Cancer Center
Phase 1/2 Withdrawn
NCT01349088 2025-05-02
Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer
Thomas Jefferson University
Phase 1/2 Withdrawn
NCT06385548 2025-04-01
LiDer
Vall d'Hebron Institute of Oncology
Phase 1/2 Withdrawn
NCT06113289 2025-03-12
A Phase 1B/2A Trial of Combination of ASTX727 With ASTX029 in Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT03764137 2025-01-31
Panitumumab
University of Alabama at Birmingham
Phase 1/2 Withdrawn
NCT05973903 2024-12-04
Lenvatinib, Pembrolizumab, and Tumor Treating Fields (TTFields) for Second-line Treatment of Glioblastoma
Tel Aviv Medical Center
Phase 1/2 Withdrawn
NCT06218667 2024-10-31
A Study of Copanlisib in Combination with Degarelix in People with Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Withdrawn
NCT05610826 2024-10-26
Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver
University of Chicago
Phase 1/2 Withdrawn
NCT04982354 2024-10-01
Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia
Baptist Health South Florida
Phase 1/2 Withdrawn
NCT06329830 2024-09-19
LUNAAR
Baptist Health South Florida
Phase 1/2 Withdrawn
NCT06586099 2024-09-19
Tislelizumab with Azacitidine in the Treatment of R/R AML
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2 Withdrawn
NCT05936229 2024-07-12
Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy
Fred Hutchinson Cancer Center
Phase 1/2 Withdrawn
NCT06080165 2024-07-10
Sirolimus for Improving Social Abilities in People With PTEN Germline Mutations
Stanford University
Phase 1/2 Withdrawn
NCT05740449 2024-06-21
HEM-iSMART A
Princess Maxima Center for Pediatric Oncology
Phase 1/2 Withdrawn
NCT05153304 2024-06-10
Personalized Immunotherapy in Adults With Upper Gastrointestinal Tract Cancers
University of California, San Diego
Phase 1/2 Withdrawn
NCT05895201 2024-04-29
High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD
Indiana University
Phase 1/2 Withdrawn
NCT03098355 2024-03-18
Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies
Zhujiang Hospital
Phase 1/2 Withdrawn
NCT05613348 2024-03-18
CAR19T2
Zhujiang Hospital
Phase 1/2 Withdrawn
NCT05201183 2023-12-11
A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic Malignancies
Indiana University
Phase 1/2 Withdrawn
NCT03735589 2023-11-22
Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Roswell Park Cancer Institute
Phase 1/2 Withdrawn
NCT02143050 2023-11-18
Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients
University of Louisville
Phase 1/2 Withdrawn
NCT04751955 2023-10-31
A Phase lb/ll, Open Label, Single Arm Study With Olinvacimab and Capecitabine in mCRC Patients (OLCAP)
Korean Cancer Study Group
Phase 1/2 Withdrawn
NCT05120622 2023-10-31
Rideau
University of British Columbia
Phase 1/2 Withdrawn
NCT04629651 2023-10-11
Captopril Use on the Degree of Marrow Fibrosis in Bone Marrow Fibrosis/Myeloproliferative Neoplasms
Case Comprehensive Cancer Center
Phase 1/2 Withdrawn
NCT05092750 2023-09-28
Magnetic Particle-ICG Lymph Node Mapping in Colorectal Cancer
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT03991104 2023-09-21
SOX-based CRT for Esophageal Cancer.
Zhejiang Provincial People's Hospital
Phase 1/2 Withdrawn
NCT04029038 2023-08-21
Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT05677373 2023-08-18
Testing the Safety and Effectiveness of Combining Two Drugs, PLX2853 and Trametinib in the Treatment of Advanced Uveal Melanoma
Alliance for Clinical Trials in Oncology
Phase 1/2 Withdrawn
NCT00455039 2023-08-14
INST 0514C- Biologic Correlative Study: Trial of GW572016 in HER2 Overexpressing Breast Cancer Patients
University of New Mexico
Phase 1/2 Withdrawn
NCT00816413 2023-08-14
Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer
University of Nebraska
Phase 1/2 Withdrawn
NCT05604417 2023-07-07
Zandelisib + Tazemetostat in R/R Follicular Lymphoma
Massachusetts General Hospital
Phase 1/2 Withdrawn
NCT04896320 2023-06-22
2019-101826
Providence Health & Services
Phase 1/2 Withdrawn
NCT05152459 2023-05-31
Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular Lymphoma
City of Hope Medical Center
Phase 1/2 Withdrawn
NCT05251038 2023-05-11
Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer
Hoosier Cancer Research Network
Phase 1/2 Withdrawn
NCT04731051 2023-04-07
The Potential Use of Inhaled Hydroxychloroquine for the Treatment of COVID-19 in Cancer Patients
King Hussein Cancer Center
Phase 1/2 Withdrawn
NCT00995059 2023-01-05
Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma
Mayo Clinic
Phase 1/2 Withdrawn
NCT01138579 2022-12-07
STP-LYM-01
Technical University of Munich
Phase 1/2 Withdrawn
NCT05570188 2022-11-30
Anti-CD19 Universal CAR-NK Cells Therapy Combined With HSCT for B Cell Hematologic Malignancies
Kunming Hope of Health Hospital
Phase 1/2 Withdrawn
NCT05433402 2022-10-27
Repurposing the Antipsychotic Drug Chlorpromazine as Adjuvant Therapeutic Agent for Resected Stage III Colon Cancer
Sadat City University
Phase 1/2 Withdrawn
NCT03709550 2022-10-05
Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer
Roswell Park Cancer Institute
Phase 1/2 Withdrawn
NCT03427320 2022-07-11
Imaging of Advanced Tumours Using [131]I-IAZA
University of Alberta
Phase 1/2 Withdrawn